Novo Nordisk Q2 2026 earnings beat, raises full-year outlook
Novo Nordisk reported Q2 2026 adjusted operating profit of 33.4 billion Danish kroner, up 11% at constant exchange rates, beating Reuters-cited analyst expectations of 28.74 billion. Net sales were 78.5 billion kroner. The company raised full-year 2026 guidance, now expecting adjusted sales and operating profit to be 0% to -6% at constant exchange rates. Wegovy demand and new launches drove results.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised 2026 outlook driven by stronger U.S. GLP-1 momentum and additional international launches, alongside disclosed adjusted vs reported profit differences.
Market read
A guidance raise with quantified Q2 results and Wegovy prescription momentum is a direct catalyst for estimate revisions and positioning ahead of the earnings call.
What to watch
The guidance range still implies contraction versus 2025, and the competitive/legal backdrop with Eli Lilly could reintroduce uncertainty despite prescription growth.
Background
Novo Nordisk’s Wegovy is its GLP-1 weight loss franchise, with ongoing international launches and regulatory approvals.
Ticker impact
Novo Nordisk raised full-year 2026 guidance after Q2 adjusted operating profit beat expectations, citing Wegovy demand and new launches.
Bias toward upside revisions and supportive price action into/after the earnings call, with volatility possible around competitive/legal overhangs.
The article discloses a specific guidance upgrade plus quantified Q2 adjusted profit and sales, and links it directly to Wegovy prescription growth and international rollout.
Market effects
Reinforces bullish read-through for GLP-1 obesity drug demand and international expansion, while highlighting ongoing competitive pressure from Eli Lilly.
Supports European pharma sentiment via a Danish large-cap earnings/guidance beat.
Signals continued global scaling of GLP-1 therapies, potentially affecting cross-market expectations for obesity drug supply and pricing.
Counterpoint
Reported operating profit fell on a one-time non-cash write-down, so the quality of earnings and pipeline asset charges could temper enthusiasm.
Key entities
- companyNovo Nordisk
Raised full-year 2026 adjusted sales and adjusted operating profit guidance after Q2 beat, citing Wegovy demand.
- productWegovy
GLP-1 weight loss pill referenced as the driver of prescription growth and guidance upgrade.
- companyEli Lilly
U.S. competitor mentioned for competitive pressure and a related U.S. lawsuit.
- regulatorEuropean Medicines Agency
Approved Wegovy and the higher-dose 7.2 mg pen in July, supporting international rollout.
